L Truemper
Overview
Explore the profile of L Truemper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaba H, Hasenkamp J, Tas H, Schulz M, Streit F, Eiffert H, et al.
J Hosp Infect
. 2023 Nov;
143:160-167.
PMID: 37939885
Background: Bacterial infection ranks amongst the most common causes of morbidity and mortality in patients undergoing allogeneic haematopoietic stem cell transplantation (alloHSCT). Although ciprofloxacin (CIP) prophylaxis is recommended, information on...
2.
Binder C, Ziepert M, Pfreundschuh M, Duhrsen U, Eimermacher H, Aldaoud A, et al.
Ann Hematol
. 2013 Aug;
92(11):1521-8.
PMID: 23978945
The rate of long-term remissions after treatment of peripheral T cell lymphomas (PTCL) with standard CHOP-like protocols is unsatisfactory. A prospective multicenter phase II trial was initiated in untreated patients...
3.
Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E, Wolf M, et al.
Ann Oncol
. 2011 Oct;
23(5):1267-1273.
PMID: 21989328
Background: To describe incidence, risk factors, and influence of treatment on occurrence of central nervous system (CNS) relapse or progression in younger patients with aggressive B-cell lymphoma. Patients And Methods:...
4.
Grgic A, Nestle U, Scheidhauer K, Puskas C, Ballek E, Hohloch K, et al.
Nuklearmedizin
. 2010 Nov;
50(1):39-47.
PMID: 21057722
Aim: Although predictive factors (PF) for conventional lymphoma therapy are established and frequently used in clinical practice and medical research, the PF for radioimmunotherapy (RIT) have not been fully defined...
5.
Dohm A, Hasenkamp J, Bertsch H, Maas J, Truemper L, Wulf G
Bone Marrow Transplant
. 2010 Aug;
46(6):899-900.
PMID: 20729923
No abstract available.
6.
Bentink S, Wessendorf S, Schwaenen C, Rosolowski M, Klapper W, Rosenwald A, et al.
Leukemia
. 2008 Jun;
22(9):1746-54.
PMID: 18580954
Deregulation of cell signaling pathways controlling cell growth and cell survival is a common feature of all cancers. Although a core repertoire of oncogenic mechanisms is widely conserved between various...
7.
Chapuy B, Koch R, Radunski U, Corsham S, Cheong N, Inagaki N, et al.
Leukemia
. 2008 May;
22(8):1576-86.
PMID: 18463677
Multidrug resistance (MDR) seriously limits the efficacy of chemotherapy in patients with cancer and leukemia. Active transport across membranes is essential for such cellular drug resistance, largely provided by ATP-binding...
8.
Thoms K, Baesecke J, Emmert B, Hermann J, Roedling T, Laspe P, et al.
Scand J Clin Lab Invest
. 2007 Sep;
67(6):580-8.
PMID: 17852814
Deficiencies in individual DNA repair systems are involved in both de novo and therapy-related acute myeloid leukaemia (t-AML), as indicated by genetic markers involving nucleotide excision repair (NER gene polymorphisms),...
9.
Hasenkamp J, Borgerding A, Wulf G, Uhrberg M, Jung W, Dingeldein S, et al.
Scand J Immunol
. 2006 Sep;
64(4):444-9.
PMID: 16970688
Target cell resistance against natural killer (NK) cell-mediated cytotoxicity obstructs NK cell-based immunotherapy of leukaemia. Several mechanisms of resistance have been described. Because of lack of simple assays for analysing...
10.
Wulf G, Sadowski B, von Bonin F, Glass B, Truemper L
Bone Marrow Transplant
. 2005 Jun;
36(2):179-80.
PMID: 15937509
No abstract available.